Predictors of severe symptomatic laboratory-confirmed SARS-CoV-2 reinfection
- PMID: 33774512
- PMCID: PMC7879028
- DOI: 10.1016/j.puhe.2021.01.021
Predictors of severe symptomatic laboratory-confirmed SARS-CoV-2 reinfection
Abstract
Objective: The aim of the study was to evaluate factors predicting severe symptomatic laboratory-confirmed (via Reverse transcription polymerase chain reaction, RT-PCR polymerase chain reaction) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection.
Study design: This is a nationwide retrospective cohort study that was conducted in Mexico.
Methods: Data from 258 reinfection cases (at least 28 days between both episodes onset) were analyzed. We used risk ratios (RRs) and 95% confidence intervals (CIs) to evaluate predictors of severe (dyspnea requiring hospital admission) secondary SARS-CoV-2 infection.
Results: The risk of severe disease was 14.7%, and the observed overall fatality rate was 4.3%. Patients with more serious primary disease were more likely to develop severe symptoms (39.5% vs. 5.5%, P < 0.001) during reinfection. In multiple analysis, factors associated with an increased risk of severe symptomatic SARS-CoV-2 reinfection were increasing age (RRper year = 1.007, 95% CI = 1.003-1.010), comorbidities (namely, obesity [RR = 1.12, 95% CI = 1.01-1.24], asthma [RR = 1.26, 95% CI = 1.06-1.50], type 2 diabetes mellitus [RR = 1.22, 95% CI = 1.07-1.38]), and previous severe laboratory-confirmed coronavirus disease 2019 (RR = 1.20, 95% CI = 1.03-1.39).
Conclusions: To the best of our knowledge, this is the first study evaluating disease outcomes in a large set of laboratory-positive cases of symptomatic SARS-CoV-2 reinfection, and factors associated with illness severity were characterized. Our results may contribute to the current knowledge of SARS-CoV-2 pathogenicity and to identify populations at increased risk of a poorer outcome after reinfection.
Keywords: COVID-19; Cohort studies; Prognosis; Reverse transcription polymerase chain reaction; Severe acute respiratory syndrome coronavirus 2.
Copyright © 2021 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.
Comment in
-
Reinfections with SARS-CoV-2 or second COVID-19 episodes?Public Health. 2021 Sep;198:e17. doi: 10.1016/j.puhe.2021.05.018. Epub 2021 May 21. Public Health. 2021. PMID: 34172305 Free PMC article. No abstract available.
Similar articles
-
Male gender and kidney illness are associated with an increased risk of severe laboratory-confirmed coronavirus disease.BMC Infect Dis. 2020 Sep 16;20(1):674. doi: 10.1186/s12879-020-05408-6. BMC Infect Dis. 2020. PMID: 32938419 Free PMC article.
-
Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients.Clin Microbiol Infect. 2021 Dec;27(12):1860.e7-1860.e10. doi: 10.1016/j.cmi.2021.07.030. Epub 2021 Aug 19. Clin Microbiol Infect. 2021. PMID: 34419576 Free PMC article.
-
Comprehensive Characterization of COVID-19 Patients with Repeatedly Positive SARS-CoV-2 Tests Using a Large U.S. Electronic Health Record Database.Microbiol Spectr. 2021 Sep 3;9(1):e0032721. doi: 10.1128/Spectrum.00327-21. Epub 2021 Aug 18. Microbiol Spectr. 2021. PMID: 34406805 Free PMC article.
-
Universal screening for SARS-CoV-2 infection: a rapid review.Cochrane Database Syst Rev. 2020 Sep 15;9(9):CD013718. doi: 10.1002/14651858.CD013718. Cochrane Database Syst Rev. 2020. PMID: 33502003 Free PMC article.
-
Repeated SARS-CoV-2 Positivity: Analysis of 123 Cases.Viruses. 2021 Mar 19;13(3):512. doi: 10.3390/v13030512. Viruses. 2021. PMID: 33808867 Free PMC article.
Cited by
-
The impact of mean body mass index on reported mortality from COVID-19 across 181 countries.Front Public Health. 2023 Mar 13;11:1106313. doi: 10.3389/fpubh.2023.1106313. eCollection 2023. Front Public Health. 2023. PMID: 36992892 Free PMC article.
-
The Effect of Varying Interval Definitions on the Prevalence of SARS-CoV-2 Reinfections: A Retrospective Cross-Sectional Cohort Study.Diagnostics (Basel). 2022 Mar 15;12(3):719. doi: 10.3390/diagnostics12030719. Diagnostics (Basel). 2022. PMID: 35328272 Free PMC article.
-
Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report.Open Forum Infect Dis. 2021 Jun 23;8(7):ofab329. doi: 10.1093/ofid/ofab329. eCollection 2021 Jul. Open Forum Infect Dis. 2021. PMID: 34337095 Free PMC article.
-
Risk of SARS-CoV-2 reinfection: a systematic review and meta-analysis.Sci Rep. 2022 Dec 1;12(1):20763. doi: 10.1038/s41598-022-24220-7. Sci Rep. 2022. PMID: 36456577 Free PMC article.
-
Does potential antibody-dependent enhancement occur during SARS-CoV-2 infection after natural infection or vaccination? A meta-analysis.BMC Infect Dis. 2022 Sep 19;22(1):742. doi: 10.1186/s12879-022-07735-2. BMC Infect Dis. 2022. PMID: 36123623 Free PMC article.
References
-
- Government of Mexico COVID-19 in Mexico: general data. https://coronavirus.gob.mx/datos/ Available at: [Webpage in Spanish]
-
- Wolfel R., Corman V.M., Guggemos W., Seilmaier M., Zange S., Muller M.A., Niemeyer D., Jones T.C., Vollmar P., Rothe C. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465–469. - PubMed
-
- Long Q.X., Liu B.Z., Deng H.J., Wu G.C., Deng K., Chen Y.K., Liao P., Qiu J.F., Lin Y., Cai X.F. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–848. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous